

COMMENTARY

- 71 | **Trials and Tribulations of Interrogating Biomarkers to Define Efficacy of Cancer Risk Reductive Interventions**
Dean E. Brenner and Ernest Hawk
See article, p. 74


RESEARCH ARTICLES

- 74 | **A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma**
Matteo Puntoni, Daniela Branchi, Alessandra Argusti, Silvia Zanardi, Cristiano Crosta, Emanuele Meroni, Francesco Munizzi, Paolo Michetti, Gianni Coccia, Giuseppe De Roberto, Roberto Bandelloni, Laura Turbino, Egle Minetti, Marco Mori, Sandra Salvi, Simona Boccardo, Beatrice Gatteschi, Roberto Benelli, Angelica Sonzogni, and Andrea DeCensi
See commentary, p. 71
- 82 | **Determination of Molecular Markers for BRCA1 and BRCA2 Heterozygosity Using Gene Expression Profiling**
Asher Y. Salmon, Mali Salmon-Divon, Tamar Zahavi, Yulia Barash, Rachel S. Levy-Drummer, Jasmine Jacob-Hirsch, and Tamar Peretz
- 91 | **Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial**
Marian L. Neuhouser, Elizabeth A. Platz, Cathee Till, Catherine M. Tangen, Phyllis J. Goodman, Alan Kristal, Howard L. Parnes, Yuzhen Tao, William D. Figg, M. Scott Lucia, Ashraful Hoque, Ann W. Hsing, Ian M. Thompson, and Michael Pollak
- 100 | **Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention**
Celine Mascaux, William J. Feser, Marina T. Lewis, Anna E. Barón, Christopher D. Coldren, Daniel T. Merrick, Timothy C. Kennedy, John I. Eckelberger, Leslie M. Rozeboom, Wilbur A. Franklin, John D. Minna, Paul A. Bunn, York E. Miller, Robert L. Keith, and Fred R. Hirsch

- 109 | **Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study**
Sara B. Jones, Gwendolyn A. Thomas, Sara D. Hesselsweet, Marty Alvarez-Reeves, Herbert Yu, and Melinda L. Irwin
- 119 | **Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration—A Clinical Pilot Study Including Assessment of Patient Acceptability**
Glen R.B. Irving, Lynne M. Howells, Stewart Sale, Ines Kralj-Hans, Wendy S. Atkin, Susan K. Clark, Robert G. Britton, Donald J.L. Jones, Edwina N. Scott, David P. Berry, David Hemingway, Andrew S. Miller, Karen Brown, Andreas J. Gescher, and William P. Steward
- 129 | **Dietary Immunosuppressants Do Not Enhance UV-Induced Skin Carcinogenesis, and Reveal Discordance between p53-Mutant Early Clones and Carcinomas**
Pieter Voskamp, Carolien A. Bodmann, Gudrun E. Koehl, Heggert G. Rebel, Marjolein G.E. Van Olderen, Andreas Gaumann, Abdoel El Ghalbzouri, Cornelis P. Tensen, Jan N. Bouwes Bavinck, Rein Willemze, Edward K. Geissler, and Frank R. De Gruijl
- 139 | **Gamma-amino Butyric Acid (GABA) Prevents the Induction of Nicotinic Receptor–Regulated Signaling by Chronic Ethanol in Pancreatic Cancer Cells and Normal Duct Epithelia**
Mohammed H. Al-Wadei, Hussein A.N. Al-Wadei, and Hildegard M. Schuller
- 149 | **Roles of Keap1–Nrf2 System in Upper Aerodigestive Tract Carcinogenesis**
Akira Ohkoshi, Takafumi Suzuki, Masao Ono, Toshimitsu Kobayashi, and Masayuki Yamamoto

ABOUT THE COVER

Immunosuppressive drugs are thought to cause the dramatically increased risk of carcinomas in sun-exposed skin of organ transplant recipients. However, the drugs differ in local effects on the skin and may thus be predictive of skin cancer risk and potentially provide guidance in minimizing the risk. In this study, the tumorigenic properties of commonly used immunosuppressants (e.g., azathioprine, cyclosporine, and rapamycin) were compared in experiments using human skin and mouse models. The cover shows a representative H&E-stained image of human skin equivalents (HSE) supplemented with rapamycin (100 nM) for a 2-week duration. Rapamycin reduced the epidermis that developed in the HSE: 3 to 4 epidermal cell layers were formed instead of 7 to 8 in the Control HSE supplemented with dimethyl sulfoxide (DMSO) (not shown). Rapamycin also decreased the proliferation index and expression of hyperproliferative markers K16 and K17 (not shown). These experiments established whether local effects of immunosuppressants on UV-induced apoptosis and p53 mutations in the skin are predictive of skin cancer risk. See article by Voskamp and colleagues (beginning on page 129) for more information.



Cancer Prevention Research

6 (2)

Cancer Prev Res 2013;6:71-159.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/6/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/6/2>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.